Managing allergic rhinitis: The role of pharmacotherapy

R. Matthew Bloebaum, J. Andrew Grant

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

While avoidance measures are a key component of the treatment of allergic rhinitis, pharmacologic therapies are often needed to adequately control symptoms. Intranasal corticosteroids are highly effective and are particularly useful in patients with moderate to severe disease. After use for 1 to 2 weeks, the patient should be reevaluated and the dose adjusted based on the response to therapy, with the goal being symptom relief at the lowest effective dose. Antihistamines, which may be given alone or with intranasal corticosteroids, control the patient's sneezing, nasal itching, rhinorrhea, and conjunctival itching. For most patients, the second- and third-generation antihistamines are better options than the first-generation antihistamines because of their superior side-effect profiles. When using cromolyn to manage seasonal symptoms, it is advisable to begin therapy 2 weeks before the expected allergen exposure. Ipratropium is helpful in patients whose main symptom is rhinorrhea.

Original languageEnglish (US)
Pages (from-to)370-376
Number of pages7
JournalJournal of Respiratory Diseases
Volume23
Issue number7
StatePublished - 2002

Fingerprint

Drug Therapy
Histamine Antagonists
Pruritus
Adrenal Cortex Hormones
Non-Sedating Histamine H1 Antagonists
Ipratropium
Sneezing
Cromolyn Sodium
Therapeutics
Nose
Allergens
Allergic Rhinitis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Bloebaum, R. M., & Grant, J. A. (2002). Managing allergic rhinitis: The role of pharmacotherapy. Journal of Respiratory Diseases, 23(7), 370-376.

Managing allergic rhinitis : The role of pharmacotherapy. / Bloebaum, R. Matthew; Grant, J. Andrew.

In: Journal of Respiratory Diseases, Vol. 23, No. 7, 2002, p. 370-376.

Research output: Contribution to journalArticle

Bloebaum, RM & Grant, JA 2002, 'Managing allergic rhinitis: The role of pharmacotherapy', Journal of Respiratory Diseases, vol. 23, no. 7, pp. 370-376.
Bloebaum, R. Matthew ; Grant, J. Andrew. / Managing allergic rhinitis : The role of pharmacotherapy. In: Journal of Respiratory Diseases. 2002 ; Vol. 23, No. 7. pp. 370-376.
@article{2da1ee8487224a5e931c31e0d749d373,
title = "Managing allergic rhinitis: The role of pharmacotherapy",
abstract = "While avoidance measures are a key component of the treatment of allergic rhinitis, pharmacologic therapies are often needed to adequately control symptoms. Intranasal corticosteroids are highly effective and are particularly useful in patients with moderate to severe disease. After use for 1 to 2 weeks, the patient should be reevaluated and the dose adjusted based on the response to therapy, with the goal being symptom relief at the lowest effective dose. Antihistamines, which may be given alone or with intranasal corticosteroids, control the patient's sneezing, nasal itching, rhinorrhea, and conjunctival itching. For most patients, the second- and third-generation antihistamines are better options than the first-generation antihistamines because of their superior side-effect profiles. When using cromolyn to manage seasonal symptoms, it is advisable to begin therapy 2 weeks before the expected allergen exposure. Ipratropium is helpful in patients whose main symptom is rhinorrhea.",
author = "Bloebaum, {R. Matthew} and Grant, {J. Andrew}",
year = "2002",
language = "English (US)",
volume = "23",
pages = "370--376",
journal = "Journal of Respiratory Diseases - For Pediatricians",
issn = "0194-259X",
publisher = "Cliggott Publishing Co.",
number = "7",

}

TY - JOUR

T1 - Managing allergic rhinitis

T2 - The role of pharmacotherapy

AU - Bloebaum, R. Matthew

AU - Grant, J. Andrew

PY - 2002

Y1 - 2002

N2 - While avoidance measures are a key component of the treatment of allergic rhinitis, pharmacologic therapies are often needed to adequately control symptoms. Intranasal corticosteroids are highly effective and are particularly useful in patients with moderate to severe disease. After use for 1 to 2 weeks, the patient should be reevaluated and the dose adjusted based on the response to therapy, with the goal being symptom relief at the lowest effective dose. Antihistamines, which may be given alone or with intranasal corticosteroids, control the patient's sneezing, nasal itching, rhinorrhea, and conjunctival itching. For most patients, the second- and third-generation antihistamines are better options than the first-generation antihistamines because of their superior side-effect profiles. When using cromolyn to manage seasonal symptoms, it is advisable to begin therapy 2 weeks before the expected allergen exposure. Ipratropium is helpful in patients whose main symptom is rhinorrhea.

AB - While avoidance measures are a key component of the treatment of allergic rhinitis, pharmacologic therapies are often needed to adequately control symptoms. Intranasal corticosteroids are highly effective and are particularly useful in patients with moderate to severe disease. After use for 1 to 2 weeks, the patient should be reevaluated and the dose adjusted based on the response to therapy, with the goal being symptom relief at the lowest effective dose. Antihistamines, which may be given alone or with intranasal corticosteroids, control the patient's sneezing, nasal itching, rhinorrhea, and conjunctival itching. For most patients, the second- and third-generation antihistamines are better options than the first-generation antihistamines because of their superior side-effect profiles. When using cromolyn to manage seasonal symptoms, it is advisable to begin therapy 2 weeks before the expected allergen exposure. Ipratropium is helpful in patients whose main symptom is rhinorrhea.

UR - http://www.scopus.com/inward/record.url?scp=0036074552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036074552&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0036074552

VL - 23

SP - 370

EP - 376

JO - Journal of Respiratory Diseases - For Pediatricians

JF - Journal of Respiratory Diseases - For Pediatricians

SN - 0194-259X

IS - 7

ER -